

***Case-based Approach:
Ischemic Heart Disease***

Daniel J. O'Rourke, MD, MS, MEd

History

- **A 68-year-old man presents to his new primary care provider for an initial patient visit. His sole active complaint is mild retrosternal chest pressure that he experiences only after significant exertion that resolves within minutes of stopping. The pattern and severity of his symptoms have not changed significantly over the last 3 years. He denies any episodes of chest pain at rest, dizziness, syncope, dyspnea, palpitations, or lower extremity edema.**

History

PMH:

- CAD – s/p PCI with BMS of the RCA ~5 years ago
- Hyperlipidemia
- HTN


Meds:

- Aspirin 81 mg QD
- Metoprolol succinate 25 mg QD
- HCTZ 12.5 mg QD
- Simvastatin 10 mg QD

He is a lifelong nonsmoker and does not consume alcohol or use illicit drugs.

Px Exam

- **Vitals – BP 155/85 HR 90**
- **Gen'l – NAD**
- **Neck – Normal JVP. 2+ carotids without murmur or bruit.**
- **Lungs – CTA B**
- **Heart – RRR. Normal S1. Physiologically split S2. No murmurs, rubs or gallops.**
- **Ext – No LE edema. 2+ pedal pulses bilaterally.**
- **ECG**



25 mm/s 10 mm/mV 150 Hz 7.1.1 12SL 239 CID: 67

EID: Newly acquired EDT: ORDE

Source: Eugene C. Toy, Michael D. Faulx:
Case Files®: Cardiology
www.mhmedical.com
Copyright © McGraw-Hill Education. All rights reserved.

Questions






- **Differential diagnosis?**
- **Diagnostic work-up?**
- **Management?**

DDx


Cardiovascular	Pulmonary	GI	MSK	Miscellaneous
Pericardium Pericarditis	Pleura Pleuritis (a.k.a. pleurisy) Pneumothorax	Esophagus GERD Esophagitis Esophageal spasm	Rib fractures Costochondritis	Severe anemia Herpes zoster (a.k.a. shingles)
Myocardium Myocarditis Heart failure exacerbation Hypertrophic cardiomyopathy Takotsubo cardiomyopathy	Airways Asthma exacerbation	Stomach Gastritis Peptic ulcer disease		Acute intoxication with cocaine or amphetamines
Valves Aortic stenosis	Alveoli Pneumonia			Acute chest syndrome in sickle cell anemia
Conduction system Tachyarrhythmias	Vessels Pulmonary embolism Pulmonary hypertension			Psychiatric Panic attack Somatization
Vessels Acute coronary syndrome Aortic dissection Hypertensive emergency	Lung cancer			

Atherosclerosis: Inflammatory Hypothesis

- *Response to injury hypothesis*
- **Atherosclerosis is considered to be a chronic inflammatory response of the arterial wall initiated by the injury to the endothelium**




Spectrum of Ischemic Heart Disease



Stress Testing

- **Type of Stress**
 - A. Exercise – Treadmill
 - B. Pharmacologic – Vasodilator or Dobutamine


- **Imaging Modality to detect ischemia**



45 year-old asymptomatic man with no risk factors

45 year-old asymptomatic man with hypercholesterolemia, hypertension, and diabetes

55 year-old man with typical angina



- The result of the exercise stress test is **NOT** dichotomous, i.e., positive or negative.
- **Rather, the test provides useful diagnostic and prognostic information.**

Extent of exercise

<4 METs vs. \geq 10 METs

BP and HR response

Chest discomfort

Duke treadmill score

Arrhythmias

O₂ saturation

Pulmonary findings – wheezes

- **Does not predict the risk for an MI**

Management

- Lifestyle modification
- Medications
 - Anti-anginal
 - Disease modifying – Aspirin & Statin therapy
- Percutaneous revascularization
- Surgical revascularization

Major risk factors for cardiovascular disease

UNHEALTHY LIFESTYLE

- Cigarette smoking
- Physical inactivity
- Diet high in fat

HIGH RISK DISEASES

- Hypertension
- Diabetes
- Hyperlipidemia
- Obesity

NON-MODIFIABLE FACTORS


- Age
- Family history of premature coronary artery disease (CAD)

END ORGAN DAMAGE

- Heart disease
- Stroke
- Peripheral artery disease
- Chronic kidney disease
- Eye sight failure


Anti-anginal Therapy

Most Common Drugs Used in Treating Angina Pectoris




Disease Modifying (Event Prevention)

- Aspirin
- Statin
- Consider ACE-I



Optimal Medical Therapy vs. Revascularization

- **Based on several randomized clinical trials, optimal medical therapy is as efficacious as PCI plus optimal medical therapy in reducing the risk of nonfatal myocardial infarction, other cardiovascular events, and death in patients with stable ischemic heart disease.**



Source: Eugene C. Toy, Michael D. Faulx:
 Case Files®: Cardiology
 www.mhmedical.com
 Copyright © McGraw-Hill Education. All rights reserved.

Clinical Pearls

- **Exercise stress testing is the preferred testing modality if the resting ECG is interpretable and the patient is able to exercise.**
- **Evaluate the patient with stable angina for signs and symptoms of left ventricular dysfunction, as this may suggest the presence of a high-risk epicardial coronary artery obstruction.**
- **Optimal medical therapy is an accepted initial management strategy in chronic stable angina without high-risk features on noninvasive testing.**
- **Titrate beta-blockers, nitrates, and calcium channel antagonists to the maximally tolerated dosages to alleviate anginal symptoms during exertion.**

History

73 year old woman presents to the ER with episodic, burning precordial chest pain occurring at rest. The pain began several hours ago while she was taking a shower and has been intermittent since. She initially attributed it to indigestion and took antacids without relief.

PMH:

- CAD (s/p PCI with DES – approx. 3 years ago)
- HTN
- Hyperlipidemia

Meds:

- Aspirin 81 mg QD
- Lisinopril 10 mg QD
- Atorvastatin 40 mg QD


Px Exam

- **Vitals – BP 168/94 HR 95 RR 20 RA ox sat 99%**
- **Gen'l – NAD**
- **Neck – Normal JVP. 2+ carotids without murmur or bruit.**
- **Lungs – CTA B**
- **Heart – RRR. Normal S1. Physiologically split S2. Soft systolic murmur at the RUSB. No gallops**
- **Ext – No LE edema. 2+ pedal pulses bilaterally.**

- **ECG**
- **Troponin +**

Referred by THOMAS, J

Unconfirmed



25 mm/s 10 mm/mV 100 Hz 005E 125 L 237 CID 39

EID-unconfirmed EDT order


Source: Eugene C. Toy, Michael D. Faulx:

Case Files®: Cardiology

www.mhmedical.com

Copyright © McGraw-Hill Education. All rights reserved.

Differential of ST Depression




- **Subendocardial ischemia**
- **LVH or enlargement**
- **Hypokalemia**
- **Bundle branch blocks**
- **Reciprocal changes in setting of MI**
- **Rate-related**
- **Neurologic**
- **Non-specific**


Questions

- **Differential diagnosis?**
- **Diagnostic work-up?**
- **Management?**

Spectrum of Ischemic Heart Disease



Pathophysiology



1

TYPE 1 MYOCARDIAL INFARCTION

Spontaneous myocardial infarction related to ischaemia due to a primary coronary event such as plaque erosion and/or rupture, fissuring or dissection

2

TYPE 2 MYOCARDIAL INFARCTION

Myocardial infarction secondary to ischaemia due to either increased oxygen demand or decreased supply

3

TYPE 3 MYOCARDIAL INFARCTION

Sudden unexpected cardiac death often with symptoms suggestive of myocardial ischaemia

4

TYPE 4 MYOCARDIAL INFARCTION

Myocardial infarction associated with percutaneous coronary intervention (4a) or stent thrombosis (4b)

5

TYPE 5 MYOCARDIAL INFARCTION

Myocardial infarction associated with cardiac surgery

Injury

MYOCARDIAL INJURY

Multifactorial aetiology; acute or chronic based on change in cardiac troponin concentrations with serial testing


Clinical Presentation

- Patients with UA/NSTEMI are **generally older and have more cardiac risk factors** compared to patients with STEMI.
- Also, more likely to have a **prior history of MI or undergone coronary revascularization.**
- Patients with NSTEMI or UA can have a **variable presentation** from recent-onset angina to progressively worsening angina within the past 48 hours to resting anginal pain (>20 minutes).
- Pain from UA/NSTEMI is **more severe and of longer duration** when compared to stable angina.
- NSTEMI differentiated from UA by presence of + troponin.

Clinical Presentation

- **Associated symptoms include SOB, diaphoresis, palpitations, nausea, or vomiting.**
- **Diabetic patients, females, or the elderly may present without chest pain.**
- **The physical exam seldom adds to the diagnosis of UA/NSTEMI.**
- **Documentation of the baseline physical exam is very important to recognize potential complications that may arise during their hospital stay, particularly the presence or absence of cardiac murmurs.**

Management Overview



Management Overview

Initial treatment goals include:

- 1. Alleviation of ischemic pain**
- 2. Optimization of hemodynamics**
- 3. Risk stratification**
- 4. Choose a management strategy**
- 5. Initiation of antithrombotic therapy.**

Initial Management

- **Aspirin 325 mg chewed**
- **Anticoagulation – unfractionated heparin, enoxaparin or bivalirudin (preferred because of lower bleeding risk)**
- **Nitrates +/- morphine**
- **High-dose statin**
- **If invasive strategy, clopidogrel, ticagrelor or prasugrel**
- **Beta-blockers should be started as soon as feasible and maintained indefinitely**

Mnemonic
Letter


Treatment

M	Morphine
O	Oxygen
N	Nitrates
A	Aspirin
R	Reperfusion (thrombolysis or primary PCI)
C	Clopidogrel (or prasugrel)
H	Heparin
B	Beta-blocker
A	Anticoagulants (aspirin and clopidogrel)
S	Statin
I	Inhibitors of angiotensin II (ACEi or A2R blocker)
C	Correction of risk factors

PCI = percutaneous coronary intervention; ACEi = angiotensin-converting enzyme inhibitor; A2R = angiotensin 2 receptor.

Management Overview

EMS= emergency medical services;
PCI = percutaneous coronary intervention.




Initial Invasive vs. Conservative Strategy

Preferred Strategy	Patient Characteristics
Invasive	Recurrent angina or ischemia at rest or with low-level activities despite intensive medical therapy Elevated cardiac biomarkers (TnT or TnI) New or presumably new ST-segment depression Signs or symptoms of HF or new or worsening mitral regurgitation High-risk findings from noninvasive testing Hemodynamic instability Sustained ventricular tachycardia PCI within 6 months Prior CABG High risk score (e.g., TIMI, GRACE) Reduced left ventricular function (LVEF less than 40%)
Conservative	Low risk score (e.g., TIMI, GRACE) Patient or physician preference in the absence of high-risk features

CABG = coronary artery bypass graft surgery; GRACE = Global Registry of Acute Coronary Events; HF = heart failure; LVEF = left ventricular ejection fraction; PCI = percutaneous coronary intervention; TIMI = Thrombolysis In Myocardial Infarction; TnI = troponin I; TnT = troponin T.

Initial Invasive vs. Conservative Strategy



Post-MI Management

- **Echocardiogram**
- **Lifestyle Modification**
- **Phase II Cardiac Rehab**
- **ACE-I if LVEF<40%, Heart Failure, DM or HTN**

Post-MI Management

β blockers

Initiate orally within 24 h if no contraindications; avoid IV without knowledge of LVEF*

Decrease myocardial oxygen demand; improve myocardial remodelling

Reduce angina, infarct size, myocardial infarction, mortality

Guidelines advise 3 years of use after myocardial infarction; indefinite if other indication (ie, heart failure)

Major studies: COMMIT, TIMI II, numerous meta-analyses

ACE inhibitors or ARBs

Initiate orally within 24 h if no contraindications†; consider ARB if intolerance or allergy

Reduce afterload; myocardial remodelling

Benefit largest in anterior STEMI, heart failure, LVEF <40%

Less benefit if low risk, no heart failure, revascularised

Angiotensin receptor-neprilysin inhibitor reduces death or hospitalisation in heart failure

Major studies: SAVE, HOPE, EUROPA, PARADIGM-HF, numerous meta-analyses

GDMT for secondary prevention

Aldosterone antagonists

Consider in patients with heart failure, LVEF <35–40%, already on adequate doses of β blocker and ACE inhibitor or ARB

Limited data on benefit without reduced LVEF

Improve myocardial remodelling; may reduce all-cause and cardiovascular mortality, and rehospitalisation

Major studies: EPHESUS, RALES, meta-analyses

Lipid-lowering therapy

Initiate high-intensity statin therapy (ie, atorvastatin 80 mg) in all patients after acute myocardial infarction

Consider ezetimibe for goal LDL <70 mg/dL (ideally ~50 mg/dL)

Reduce mortality, subsequent cardiovascular events, and may reduce readmission‡

Major studies: A-to-Z, PROVE-IT, IMPROVE-IT

Antiplatelet therapy (aspirin, P2Y12 inhibitor)‡

Aspirin—indefinite low dose (81–100 mg), reduces mortality

DAPT (aspirin + clopidogrel/prasugrel/ticagrelor)—reduces ischaemic events and mortality (ticagrelor only)

Major studies: CURE, CREDO, TRITON-TIMI 38, PLATO, CHARISMA, DAPT, PEGASUS

Clinical Pearls

- **UA/NSTEMI is typically due to reduced blood flow due to a non-occlusive thrombus that forms on an atherosclerotic plaque.**
- **UA and NSTEMI are clinically indistinguishable.**
- **UA/NSTEMI may present with ST segment depression, T wave inversion, or no ECG changes at all.**
- **UA/NSTEMI patients should be risk-stratified and referred for an early invasive therapy if indicated.**
- **Risk factor modification and maintenance of an evidence-based medical regimen are essential for secondary prevention.**
- **Monitor for potential electrical or mechanical complications of ACS.**

History

- **62 year old man arrives to the ER complaining of acute, severe precordial chest pain radiating to his arm and neck.**
- **The pain is described as “an elephant standing on my chest” and accompanied by nausea.**
- **Chest pain began approximately 30 minutes ago while he was watching television and has not completely resolved.**
- **PMH: HTN, hyperlipidemia, 50-pack/year tobacco history**

Px Exam

- **Vitals – BP 156/97 HR 113 RR 24 RA ox sat 98%**
- **Gen'l – Appears to be in moderate distress**
- **Neck – Normal JVP. 2+ carotids with left bruit.**
- **Lungs – Faint crackles at the bases.**
- **Abd – Soft, +BS, NT, ND**
- **Heart – Tachycardic. Regular. Normal S1, S2. No murmur or gallop.**
- **Ext – No LE edema. 2+ pedal pulses bilaterally.**

Questions

- **Differential diagnosis?**
- **Diagnostic work-up?**
- **Management?**

CRITICAL


- Acute Coronary Syndromes
 - STEMI
 - Non-STEMI
 - Unstable angina
- Aortic Dissection
- Cardiac Tamponade
- Pulmonary Embolism
- Tension Pneumothorax

Emergent

- Pericarditis
- Myocarditis
- Pneumothorax
- Mediastinitis
- Cholecystitis
- Pancreatitis
- Cocaine chest pain

Non Emergent

- Stable angina
- Asthma exacerbation
- Valvular Heart Disease
- Pneumonia
- Pleuritis
- Tumor
- Esophageal Spasm
- Gastroesophageal Reflux Disease (GERD)
- Peptic Ulcer Disease
- Biliary Colic
- Rib Fracture
- Chostochondirits
- Panic attack




Differential of ST Elevation


EMNote


ST Elevation - Not Always AMI



Mnemonic for causes of ST elevation : **"ELEVATION"**

- E** : Electrolytes (e.g. hyperkalemia)
- L** : Left bundle branch block
- E** : (Benign) Early repolarization
- V** : Ventricular hypertrophy
- A** : Arrhythmia (Brugada, VT), Aneurysm of LV, Aortic dissection
- T** : Takotsubo disease, Traumatic brain injury (ICH)
- I** : Infarct (MI), Injury(contusion), Inflammation (myo/peri-carditis)
- O** : Osborn (J) waves (hypothermia or hypercalcemia)
- N** : Non-atherosclerotic vasospasm (Prinzmetal's angina)












Basal



Mid



Apical



Clinical Presentation

- Majority of patients describe a crushing, heavy, pressure, or squeezing sensation.
- Radiation to the left arm or jaw is classic, although radiation to the back, right arm, shoulder, and epigastric region are also seen.
- The character can be similar to stable angina; however, the pain associated with STEMI is of longer duration, not relieved by NTG and more intense.
- Associated symptoms include dyspnea, diaphoresis, palpitations, nausea, vomiting, extreme fatigue, or an impending sense of doom.
- Women, diabetics or the elderly may present without chest pain, only describing a nonspecific discomfort in combination other sx's

STEMI pt who is a
candidate for reperfusion

Preferred for FMC to ECG and diagnosis	≤10 min
Preferred for FMC to fibrinolysis ('FMC to needle')	≤30 min
Preferred for FMC to primary PCI ('door to balloon') in primary PCI hospitals	≤60 min
Preferred for FMC to primary PCI	≤90 min (≤60 min if early presenter with large area at risk)
Acceptable for primary PCI rather than fibrinolysis	≤120 min (≤90 min if early presenter with large area at risk) if this target cannot be met, consider fibrinolysis.
Preferred for successful fibrinolysis to angiography	3–24 h

FMC = first medical contact; PCI = percutaneous coronary intervention.

Table 2: Contraindications to Thrombolytic Therapy

Absolute Contraindications

Any prior intracranial hemorrhage

Known intracranial malformation or neoplasm

Ischemic stroke <3 month

Suspected dissection

Recent surgery

Recent head trauma

Bleeding diathesis

Relative Contraindications

>75 years of age

Current anticoagulants

Pregnancy

Cardiopulmonary resuscitation >10 minutes

Recent internal bleed (2–4 weeks)

Uncontrolled hypertension (180/110 mmHg)

Remote ischemic stroke

Major surgery within 3 weeks

Modified from Jaff et al.³⁹

Initial Management

- **Aspirin 325 mg chewed**
- **Anticoagulation – unfractionated heparin, enoxaparin or bivalirudin (preferred because of lower bleeding risk)**
- **Nitrates +/- morphine**
- **High-dose statin**
- **Beta-blockers should be started as soon as feasible and maintained indefinitely**

Treatment

Mnemonic Letter	Treatment
M	Morphine
O	Oxygen
N	Nitrates
A	Aspirin
R	Reperfusion (thrombolysis or primary PCI)
C	Clopidogrel (or prasugrel)
H	Heparin
B	Beta-blocker
A	Anticoagulants (aspirin and clopidogrel)
S	Statin
I	Inhibitors of angiotensin II (ACEi or A2R blocker)
C	Correction of risk factors

PCI = percutaneous coronary intervention; ACEi = angiotensin-converting enzyme inhibitor; A2R = angiotensin 2 receptor.


M

722010-1007100129/08-50191
10-Mar-2015
Ser: -
Imm: 1/1 Fr: 25/54

RAO: -36.1°
CAUD: -17.03°
Zoom: 1.00x

AlluraXper
DFOV: 13.2 x 13.2 cm

722010-1007100129/08-50191



Cardiac Stents

- **Drug-eluting stents (DES)**


- Anti-proliferative drug to help prevent restenosis


- Used in 80% of PCI

- Aspirin and plavix at least 6 months, ideally 1 year

- **Bare metal stents (BMS)**

- Aspirin and clopidogrel for at least 1 month





Ventricular arrhythmias
(ventricular fibrillation or tachycardia)
Primary: due to ischaemia; onset <4 h
Secondary: due to remodelling or scar; onset >48 h

Bradyarrhythmias/ heart block
Common, especially with inferior myocardial infarction
Often resolve spontaneously if onset <24 h

Cardiogenic shock
Strongly dependent on infarct size; 5–6% of patients with STEMI

Stroke
Thromboembolic from PCI or haemorrhagic from antithrombotic therapy
Long-term risk in large anterior infarct, left ventricular aneurysm, or reduced left ventricular ejection fraction

Ischaemic MR/papillary muscle rupture
Posterior papillary muscle most often; supplied by dominant artery
Characteristic murmur of MR may be absent

Ventricular septal rupture
Most common with anterior myocardial infarction
Holosystolic murmur at LSB

LV free wall rupture
Persistent STE, upright T-waves, reversal of initially inverted T-waves
>50% mortality even with surgery


Pericarditis (Dressler syndrome)
Autoimmune reaction; more common in large infarcts
Persistent STE, PR depression, may have a friction rub




Disease Modifying (Secondary Prevention)

- Aspirin 81 mg QD – lifelong
- Beta Blocker (anti-arrhythmic & remodeling)
- ACE-I (remodeling)
- Statin (Goal <70 mg/dl) – lifelong

Aspirin



LDL-C Is Closely Related to CHD Events¹



- Adapted from Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. *Am J Cardiol.* 1998;82:3Q-12Q, with permission from Excerpta Medica.
- Heart Protection Study Collaborative Group. *Lancet.* 2002;360:7-22.

Clinical Pearls

- **STEMI is due to complete occlusion of a coronary artery characterized by ≥ 1 mm ST elevation in 2+ contiguous leads.**
- **The location of ST elevation correlates with the occluded artery.**
- **Women, diabetics and the elderly may present with atypical or vague symptoms.**
- **Reperfusion therapy is of the essence and should be initiated ASAP. Ideal “door-to-balloon” time is < 90 minutes or, if PCI is not available, fibrinolytics should be administered within 30 minutes.**
- **After STEMI, risk factor modification and an evidence-based cardioprotective medical regimen consisting of aspirin, ADP inhibitor, high-dose statin, BB and ACE-I are essential.**
- **Monitor for potential electrical or mechanical complications of ACS.**